September 2021

New Data Presented at World Muscle Society 2021 Virtual Congress

Leave a Comment / Front Page News, Industry Updates, Research /

This week, new data was presented at the World Muscle Society 2021 Virtual Congress. Check it out below!     Scholar Rock presents two posters featuring additional analyses from the TOPAZ phase 2 trial of Apitegromab: Poster: Apitegromab in Spinal Muscular Atrophy (SMA): An Analysis of Multiple Efficacy Endpoints in the TOPAZ Trial (LBP.10) This […]

New Data Presented at World Muscle Society 2021 Virtual Congress Read More »

Community Statement from Biogen: New Clinical Study Planned to Evaluate the Potential Benefit of an Investigational Higher Dose of Nusinersen in People with SMA Previously Treated with Evrysdi® (risdiplam)

Leave a Comment / Front Page News, Industry Updates /

Biogen is committed to improving health outcomes for people impacted by spinal muscular atrophy (SMA) and generating data to assess if there are treatment pathways to address potential unmet needs. Today, we are excited to announce our intent to initiate a new global SMA clinical trial called ASCEND to understand whether an investigational higher dose

Community Statement from Biogen: New Clinical Study Planned to Evaluate the Potential Benefit of an Investigational Higher Dose of Nusinersen in People with SMA Previously Treated with Evrysdi® (risdiplam) Read More »

Scroll to Top